Bibliotecas PUC-SP - Busca Integrada

Analysis of prognostic factors for survival in the Russian population of patients with disseminated gastric cancer, who received ramucirumab as secondline therapy in the RAMSELGA t...

per N. S. Besova, T. A. Titova, Е. V. Artamonova, A. A. Tryakin, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukalchuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, I. S. Stilidi
Publicat a Медицинский совет (2020-07-01)

Anemia in people on second line antiretroviral treatment in Lilongwe, Malawi: a cross-sectional study

per McNeil Ngongondo, Nora E. Rosenberg, Christopher C. Stanley, Robertino Lim, Dennis Ongubo, Richard Broadhurst, Colin Speight, Robert Flick, Petros Tembo, Mina C. Hosseinpour
Publicat a BMC Infectious Diseases (2018-01-01)

Avelumab treatment in Italian patients with metastatic Merkel cell carcinoma: experience from an expanded access program

per Giovanni Grignani, Vanna Chiarion Sileni, Carmine Pinto, Roberta Depenni, Nicola Fazio, Luca Galli, Dario Giuffrida, Carlo Carnaghi, Domenico Ciliberto, Domenico C. Corsi, Paola Queirolo, Elena Benincasa, Filippo Venturini, Gennaro Fazzi, Nuno Costa, Paolo Antonio Ascierto
Publicat a Journal of Translational Medicine (2021-02-01)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts

per Francesca Ricci, Federica Guffanti, Giovanna Damia, Massimo Broggini
Publicat a Molecular Cancer (2017-05-01)

A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe...

per Dennis Miyoge Ongubo, Robertino Lim, Hannock Tweya, Christopher Chikhosi Stanley, Petros Tembo, Richard Broadhurst, Salem Gugsa, McNeil Ngongondo, Colin Speight, Tom Heller, Sam Phiri, Mina C. Hosseinipour
Publicat a BMC Infectious Diseases (2017-07-01)

Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma

per Iraklis C. Mitsogiannis, Maria Mitsogianni, Maria Papathanassiou, Maria Anagnostou, Ioannis Tamposis, Lampros Mitrakas, Maria Samara, Vassilios Tzortzis, Panagiotis J. Vlachostergios
Publicat a Journal of Kidney Cancer and VHL (2022-09-01)

Drug susceptibilities of Mycobacterium tuberculosis against injectable second-line drugs from Pakistan: Analysis of multidrug-resistant and non-multidrug-resistant tuberculosis str...

per Kauser Jabeen, Joveria Farooqi, Samreen Shafiq, Faisal Malik, Rumina Hasan
Publicat a International Journal of Mycobacteriology (2015-01-01)

Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn’s disease: a multicentre retrospective study

per Rayer Cassandra, Maria Nachury, Bourreille Arnaud, Roblin Xavier, Peyrin-Biroulet Laurent, Viennot Stephanie, Flamant Mathurin, Laharie David, Caron Bénédicte, Dewitte Marie, Siproudhis Laurent, Fumery Mathurin, Bouguen Guillaume
Publicat a BMC Gastroenterology (2022-12-01)

Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study

per Wolfgang M. Brueckl, H. Jost Achenbach, Joachim H. Ficker, Wolfgang Schuette
Publicat a BMC Cancer (2018-03-01)

Focus on Alectinib and Competitor Compounds for Second Line Therapy in ALK Rearranged NSCLC

per Samuel J Klempner, Samuel J Klempner, Phu Tran
Publicat a Frontiers in Medicine (2016-11-01)

FOLFOX vs FOLFIRI as Second-line of Therapy After Progression to Gemcitabine/Nab-paclitaxel in Patients with Metastatic Pancreatic Cancer

per Catalano M, Conca R, Petrioli R, Ramello M, Roviello G
Publicat a Cancer Management and Research (2020-10-01)

Hepatocellular carcinoma after prior sorafenib treatment: incidence, healthcare utilisation and costs from German statutory health insurance claims data

per Johannes Clouth, Astra M. Liepa, Guido Moeser, Heiko Friedel, Magdalena Bernzen, Jörg Trojan, Elena Garal-Pantaler
Publicat a Health Economics Review (2018-08-01)

HIV drug resistance, early treatment outcomes and impact of guidelines compliance after protease inhibitor‐based second‐line failure in a dedicated resistance clinic in western Ken...

per John M. Humphrey, Shamim M. Ali, Allison DeLong, Vlad Novitsky, Edwin Sang, Bilal Jawed, Emmanuel Kemboi, Celia Ngetich, Suzanne Goodrich, Adrian Gardner, Joseph W. Hogan, Rami Kantor
Publicat a Journal of the International AIDS Society (2025-06-01)

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis

per Antonio Galvano, Lorena Incorvaia, Giuseppe Badalamenti, Sergio Rizzo, Aurelia Guarini, Stefania Cusenza, Luisa Castellana, Nadia Barraco, Valentina Calò, Sofia Cutaia, Giuseppe Currò, Nicola Silvestris, Giordano Domenico Beretta, Viviana Bazan, Antonio Russo
Publicat a Cancers (2019-08-01)

Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience

per Martin Rupp, Fiorella Fanton-Aita, Stephanie Snow, Paul Wheatley-Price, Barbara Melosky, Rosalyn A. Juergens, Quincy Chu, Normand Blais, Shantanu Banerji, Ryan Ng, Shoghag Khoudigian, Arushi Sharma, Phu Vinh On, Geoffrey Liu
Publicat a Current Oncology (2023-07-01)

Low-level viraemia despite emergence of dolutegravir-resistant variants

per Johannes C. Botha, Kim Steegen, Mariam Edoo, Jeremy Nel, Gert U. van Zyl
Publicat a Southern African Journal of HIV Medicine (2022-09-01)

Lurbinectedin in small cell lung cancer

per Anna Manzo, Vincenzo Sforza, Guido Carillio, Giuliano Palumbo, Agnese Montanino, Claudia Sandomenico, Raffaele Costanzo, Giovanna Esposito, Francesca Laudato, Edoardo Mercadante, Carmine La Manna, Paolo Muto, Giuseppe Totaro, Rossella De Cecio, Carmine Picone, Maria Carmela Piccirillo, Giacomo Pascarella, Nicola Normanno, Nicola Normanno, Alessandro Morabito
Publicat a Frontiers in Oncology (2022-08-01)

Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel

per Taro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, Junichi Nakazawa, Shiho Arima, Masaru Fukahori, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Akitaka Makiyama, Hozumi Shimokawa, Shigeyuki Takeshita, Kazuo Nishikawa, Azusa Komori, Satoshi Otsu, Ayumu Hosokawa, Tatsunori Sakai, Hisanobu Oda, Machiko Kawahira, Shuji Arita, Takuya Honda, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Kenta Nio, Yasushi Ide, Norio Ureshino, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi
Publicat a Scientific Reports (2024-07-01)

Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Grou...

per Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara, Juan L. Marti, Rafael López Castro, Ana Laura Ortega, Elia Martínez Moreno, Juan Coves, Ana M. Sánchez Peña, Joaquim Bosch-Barrera, Amparo Sánchez Gastaldo, Natalia Fernández Núñez, Edel del Barco, Manuel Cobo, Dolores Isla, Margarita Majem, Fátima Navarro, Virginia Calvo
Publicat a BMC Cancer (2021-03-01)

Pediatric immune thrombocytopenia: a focus on eltrombopag as second-line therapy

per Giuseppe Palumbo, Piero Farruggia, Ugo Ramenghi, Giovanna Russo, Alessandra Borchiellini, Marco Spinelli, Carlo Dufour, Fiorina Giona, Saverio Ladogana, Marco Zecca, Silverio Perrotta, Andrea Pession, Paola Giordano
Publicat a Hematology (2023-12-01)